Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio Group

12.42 EUR-17.75 %8/9 17:29
14,542 following

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-17.75 %
-8.41 %
-5.62 %
-31.38 %
-44.55 %
-46.92 %
-44.90 %
-80.44 %
+553.68 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
362.25M EUR
Turnover
9.17M EUR
P/E (adj.) (26e)
14.96
EV/EBIT (adj.) (26e)
17.24
P/B (26e)
1.69
EV/S (26e)
2.83
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
20.00 EUR
Updated
2026-08-31
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-08-31

Latest extensive report

Released: 2025-01-21

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Yes, there is, that’s what I’ve been trying to prepare for here using the new data. Based on the pro formas, the key figures looked to me just like what was communicated. H1’26 is still tricky to interpret, but 2025 is. Financing is being overhauled anyway, so these don’t matter ...
10 hours ago
by Juha Kinnunen
58
Yup, looks like a very ugly earnings miss unless there are explaining factors behind the headline numbers. AI did pick up that one-off costs were 3.4 million euros instead of the 3.0 million euros expected by Inderes. So an explanation isn’t found here to a sufficient degree either...
12 hours ago
by Lexus
25
I jumped off Revenio’s bandwagon about a year ago at around the 24 euro price level when the company’s growth outlook seemed to be sputtering and earnings per share were on a downward trend. I figured you can get higher-quality business and better growth at a better price elsewhere...
10 hours ago
24
Here is indeed the interview from today for you all, in case anyone missed it on other channels!
3 hours ago
by Tomi Valkeajärvi
13
Is @Juha_Kinnunen having the CEO interview today like before? Looking at the pro forma figures from last year, losses were made regarding Visionix. Is this due to old financing arrangements or something else, since the financial expenses were quite high, nevertheless? At the latest...
11 hours ago
by Temew
13
On the other hand, the aforementioned trough, not the ATL, is from less than a month ago, and back then there was no knowledge of clearly lower demand for basic Revenio products. I wouldn’t be surprised if the ten-euro mark is tested soon, unless the conference call provides a good...
11 hours ago
by Expaco_b
11
Are they actually trying to talk the market down now that there’s a chance, so that accumulation (tankkaaminen) can happen more cheaply ? As I said, I see the numbers of this chaotic period as slightly positive. Slightly, because risks certainly exist. Having been involved in real...
11 hours ago
by Sissos
8
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8/9
2026

Interim report Q2'26

11/11
2026

Interim report Q3'26

Revenio, Audiocast, Q2'26
Webcast2026-09-08 14:00

Revenio, Audiocast, Q2'26

Revenio Group
Regulatory press release2026-09-08 08:00

Revenio Group Corporation: Half-Year Report January 1 – June 30, 2026

Revenio Group
Press release2026-09-03 13:00

Modular Finance IR Consensus: Revenio Group – Consensus estimates Q2 2026

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Revenio Group Capital Markets Day 2026
Webcast2026-09-15 13:00

Revenio Group Capital Markets Day 2026

At the Capital Markets Day, the company's key personnel will present an in-depth overview of Revenio's strategy.

Revenio Group
Revenio Q2'26 preview: First step for new vision
Research2026-08-31 09:25 by
Juha Kinnunen

Revenio Q2'26 preview: First step for new vision

Revenio's Q2 report also includes a one-month contribution from the Visionix acquisition.

Revenio Group
Press release2026-08-27 08:00

Revenio’s Half-year report January-June 2026 to be published on September 8, 2026

Revenio Group
Press release2026-08-20 14:30

Invitation to Revenio Group’s Capital Markets Day 2026

Revenio Group
Revenio: iCare's AI partner received green light from FDA
Analyst Comment2026-08-17 09:52 by
Juha Kinnunen

Revenio: iCare's AI partner received green light from FDA

The first FDA approval for the combination of the iCare imaging device and AI removes uncertainty and supports growth in device sales in the United States.

Revenio Group
Press release2026-08-17 08:00

Revenio’s iCare DRSplus included in FDA-cleared AI solution for diabetic retinopathy screening

Revenio Group
Regulatory press release2026-08-12 12:00

Jukka Kainulainen starts as Revenio CFO on August 24, 2026

Revenio Group
Revenio: iCare strengthens its foothold in the US screening market with EyeCheq partnership
Analyst Comment2026-08-07 07:57 by
Juha Kinnunen

Revenio: iCare strengthens its foothold in the US screening market with EyeCheq partnership

The strategic partnership can expand the availability of iCare devices in the United States.

Revenio Group
Press release2026-08-06 15:00

Revenio Group’s iCare and EyeCheq announce strategic partnership and minority investment

Revenio Group
Regulatory press release2026-08-05 13:00

Revenio’s updated Disclosure Policy is published

Revenio Group
Revenio: Visionix integration progresses as planned
Analyst Comment2026-08-03 08:04 by
Juha Kinnunen

Revenio: Visionix integration progresses as planned

The company aims for an EBITDA improvement of over 20 MEUR through Visionix synergies by the end of 2029.

Revenio Group
Press release2026-07-31 11:50

Revenio provides an update on the Visionix integration progress and announces changes in the U.S. organization

Revenio Group
Regulatory press release2026-06-30 08:00

Revenio Group Corporation’s Board of Directors resolved on the long-term incentive plan’s performance period 2026–2028 and launch of a new restricted share plan

Revenio Group
Regulatory press release2026-06-12 09:00

Revenio Group Corporation: Managers' Transactions – Marc Abitbol Consulting Service Ltd.

Revenio Group
Regulatory press release2026-06-11 11:20

Correction: Changes to the publication dates of Revenio’s financial reports in 2026

Revenio Group
Regulatory press release2026-06-10 18:00

Changes to the publication dates of Revenio’s financial reports in 2026

Revenio Group
Regulatory press release2026-06-10 18:00

Board of Directors of Revenio has established Technology and Integration Committees

Revenio Group